First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤ANB033 protected against gluten-induced intestinal damage and symptoms in Phase 1b CeD Cohort 1
- ➤ANB033 CeD Cohort 2 enrollment complete; top-line data expected in Q1 2027
- ➤First Tracks expects late-stage ANB033 CeD trial initiation in 2027
- ➤$200 million private placement completed; pro forma cash reached $343 million
- ➤Third-quarter net loss $31.4 million, or $0.88 per share, versus $41.9 million loss
Expert Statements
Daniel Faga, President and Chief Executive Officer of First Tracks Biotherapeutics
“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort.”
Daniel Faga, President and Chief Executive Officer of First Tracks Biotherapeutics
“These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet”
Daniel Faga, President and Chief Executive Officer of First Tracks Biotherapeutics
“We will continue to work with regulators, clinicians and the patient community to advance ANB033. We anticipate initiating Phase 2 development in vitiligo and one additional indication in the first half of 2027, and reporting top-line results from the celiac disease mucosal-healing cohort in the first quarter of 2027 and in eosinophilic esophagitis in the third quarter of 2027.”
* Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) * Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in CeD; top-line data anticipated in Q1 2027 * Anticipate initiating late-stage clinical trial for ANB033 in CeD in 2027 * Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-line data anticipated in Q3 2027 * Anticipate initiating Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027 * Completed private placement with $200 million in gross proceeds; pro forma cash of $343 million SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the third quarter ended Sept. 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.